BESPONSA is a CD22-directed antibody-drug conjugate (ADC) indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of BESPONSA (inotuzumab ozogamicin) for injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the BESPONSA (inotuzumab ozogamicin) for injection medicine cost price in India.
The order for BESPONSA (inotuzumab ozogamicin) for injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Inotuzumab ozogamicin (trade name Besponsa) is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The medication consists of the humanized monoclonal antibody against CD22 (inotuzumab), linked to a cytotoxic agent from the class of calicheamicins called ozogamicin.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous use Initial U.S. Approval: 2017
Generic Name: inotuzumab ozogamicin
For injection: 0.9 mg lyophilized powder in a single-dose vial for reconstitution and further dilution.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand BESPONSA (inotuzumab ozogamicin) for injection on prescription and Import License in Patient's Name only.
For overseas patients, BESPONSA (inotuzumab ozogamicin) for injection can be made available in Send your enquiry to find BESPONSA (inotuzumab ozogamicin) for injection in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For BESPONSA (inotuzumab ozogamicin) for injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic For More Details
FDA Grants Inotuzumab Ozogamicin Breakthrough Status for ALL For More Details